Stocks That Can Potentially Compound Wealth Over Decades

In 1980, a young investor put $10,000 into a company run by a folksy insurance executive in Omaha, Nebraska. No fancy algorithm, no day-trading strategy, no leverage. Just a single purchase — and then decades of doing absolutely nothing. By 2025, that $10,000 had grown to over $4.2 million. The company was Berkshire Hathaway, and the investor’s only real skill was patience.

Here is the uncomfortable truth about building serious wealth in the stock market: the biggest fortunes are not made by the smartest traders or the most sophisticated quant models. They are made by people who identify extraordinary businesses early, buy them at reasonable prices, and then hold on through every recession, every correction, every panic — for decades. These businesses are called compounders, and they are the closest thing the stock market offers to a cheat code for wealth creation.

But finding a compounder is only half the battle. The other half — the harder half — is holding it. Study after study shows that the average investor underperforms even the index funds they invest in, largely because they sell at the worst possible times. The psychology of compounding works against our human instincts at every turn.

In this deep dive, we will break down exactly what makes a stock a compounder, walk through the historical giants that turned modest investments into life-changing wealth, do the actual math of long-term returns, identify current candidates for the next generation of compounders, and confront the behavioral challenges that prevent most people from ever capturing these gains. Whether you are a beginner investor or a seasoned market participant, understanding the compounding machine is the single most important concept in all of investing.

What Makes a Compounder

Not every stock that goes up is a compounder. Plenty of stocks double or triple on a short-term catalyst — a hot product launch, a favorable regulatory decision, a speculative bubble — and then fade back to mediocrity. A true compounder is fundamentally different. It is a business that can grow its intrinsic value at a high rate for an extended period, typically 15 or more years, driven by durable competitive advantages and intelligent capital allocation.

Let us break down the four pillars that separate genuine compounders from everything else.

High Return on Invested Capital (ROIC)

ROIC is the single most important financial metric for identifying compounders. It tells you how efficiently a company converts the capital it invests — in factories, technology, acquisitions, research — into profits. A company earning a 25% ROIC generates $25 of operating profit for every $100 it invests. A company earning 8% ROIC generates just $8.

Why does this matter so much? Because when a high-ROIC business reinvests its earnings back into the business, each dollar reinvested generates outsized returns. Over years and decades, this creates an exponential growth curve that is nearly impossible to replicate through financial engineering or cost-cutting alone.

Companies like Visa, Mastercard, and Adobe routinely post ROIC figures above 30%. These are not anomalies — they are reflections of business models that require relatively little capital to generate enormous profits. Compare that to a capital-intensive airline or steel manufacturer that needs to constantly plow money into physical assets just to maintain its operations.

Long Reinvestment Runway

High ROIC alone is not enough. A small niche business might earn fantastic returns on capital, but if its addressable market is tiny, it will run out of places to reinvest those profits. The growth engine stalls, and the company becomes a cash cow — profitable but no longer a compounder.

True compounders operate in markets that are either enormous to begin with or expanding rapidly. Think about Amazon in 2005. It dominated online book sales, but the total addressable market for e-commerce, cloud computing, advertising, and logistics was so vast that the company could reinvest aggressively for two more decades and still find new frontiers.

When evaluating reinvestment runway, ask yourself: Can this company double, triple, or quadruple its revenue over the next decade without entering entirely unfamiliar territory? If the answer is yes, and the ROIC stays high, you may be looking at a compounder.

Durable Competitive Moat

A moat is the economic barrier that prevents competitors from eroding a company’s profit margins. Warren Buffett popularized this concept, and it remains the cornerstone of long-term investing. Without a moat, high returns attract competitors like blood attracts sharks — margins get competed away, ROIC declines, and the compounding engine breaks down.

The strongest moats come in several forms:

• Network effects: Visa and Mastercard become more valuable as more merchants and cardholders join their networks. Each new participant makes the network more attractive to the next one.
• Switching costs: Once a hospital system builds its operations around Intuitive Surgical’s da Vinci robots, switching to a competitor would require retraining thousands of surgeons and replacing millions of dollars in equipment.
• Intangible assets: S&P Global’s credit ratings are embedded in financial regulations worldwide. You cannot simply launch a competing rating agency — the regulatory moat is immense.
• Cost advantages: Costco’s scale allows it to buy in massive volume and pass savings to members, creating a flywheel that smaller competitors cannot match.
• Data and ecosystem lock-in: Microsoft’s Office and Azure ecosystem creates deep integration across enterprise workflows that makes switching extraordinarily painful.

Pricing Power

Buffett once said that the single most important decision in evaluating a business is pricing power. “If you’ve got the power to raise prices without losing business to a competitor, you’ve got a very good business.” This is a crucial insight because inflation, rising wages, and increasing input costs are constant threats to profitability. A business with pricing power can pass these costs on to customers without losing volume.

Consider Moody’s Corporation. When a company needs to issue bonds, it essentially must get a rating from Moody’s or S&P Global. There is no real alternative. If Moody’s raises its fees by 5%, bond issuers grumble — and then pay. That is pricing power in its purest form.

Contrast that with a commodity producer or a low-cost retailer competing on price. These businesses face constant margin pressure and have limited ability to raise prices without losing customers. They can be profitable, but they rarely compound wealth at the rates we are discussing.

The Compounder Characteristics Checklist

Historical Compounders That Turned $10K Into $1M+

Theory is useful, but nothing drives the point home like real numbers. Let us look at some of the greatest compounders in stock market history and trace what a $10,000 investment would be worth today — assuming you had the conviction and patience to hold through every storm.

Berkshire Hathaway (BRK.A)

Berkshire Hathaway is the gold standard of compounding. When Warren Buffett took control in 1965, the stock traded around $19 per share. By early 2025, a single Class A share traded above $700,000. A $10,000 investment in 1965 would be worth approximately $420 million — a number so absurd it almost defies belief.

Even investors who bought later did extraordinarily well. A $10,000 investment in 1980 grew to roughly $4.2 million by 2025. The secret was not any single brilliant trade but rather Buffett’s disciplined approach to buying wonderful businesses at fair prices and letting the compounding do its work over decades.

Berkshire’s CAGR from 1965 to 2024 was approximately 19.8% — compared to 10.2% for the S&P 500 over the same period. That 9.6 percentage point annual difference, compounded over 59 years, is the difference between comfortable wealth and dynastic fortune.

Apple (AAPL)

Apple’s compounding story is remarkable because the company nearly went bankrupt in 1997 before Steve Jobs returned and orchestrated one of the greatest corporate turnarounds in history. A $10,000 investment in Apple at the start of 2003 — when the stock was trading around $1 split-adjusted — would be worth approximately $2.8 million by early 2025.

What made Apple a compounder? The iPhone created an ecosystem with massive switching costs. Once users invested in apps, iCloud storage, Apple Watch, AirPods, and the broader ecosystem, leaving became increasingly costly. Apple’s services revenue — the App Store, Apple Music, iCloud, Apple TV+ — now generates over $95 billion annually at margins north of 70%, creating a recurring revenue stream on top of hardware sales.

Amazon (AMZN)

Amazon’s IPO in May 1997 priced at $18 per share. A $10,000 investment at that price, adjusted for splits, would be worth approximately $2.2 million by 2025. But the journey was anything but smooth — the stock dropped 94% from its peak during the dot-com bust, falling from over $100 to under $6. Most investors sold in terror. The ones who held became millionaires.

Amazon epitomizes the long reinvestment runway. Jeff Bezos famously prioritized growth and market share over short-term profits, reinvesting virtually every dollar back into the business. This strategy looked reckless for years — Wall Street constantly criticized Amazon’s thin margins — but it allowed the company to build logistics infrastructure, launch AWS, and dominate e-commerce in ways that competitors simply could not match.

Microsoft (MSFT)

Microsoft is a fascinating compounding story because it happened in two distinct phases. The first phase, from its 1986 IPO through 2000, was explosive growth driven by Windows and Office. Then the stock went essentially nowhere for 14 years, from 2000 to 2014, as the company missed the mobile revolution under Steve Ballmer.

The second phase began when Satya Nadella took over as CEO in 2014 and pivoted the company aggressively toward cloud computing. Azure became the second-largest cloud platform in the world, and Microsoft’s stock went from $36 in early 2014 to over $420 by early 2025 — a nearly 12x return in just over a decade.

A $10,000 investment at Microsoft’s IPO would be worth approximately $4.5 million today. Even a $10,000 investment as late as 2014, when Nadella took over, would be worth roughly $120,000.

Costco (COST)

Costco is the most underappreciated compounder on this list. It does not have the glamour of a tech giant, but its membership-based business model creates a powerful flywheel: low prices attract members, membership fees fund operations, scale drives even lower prices, which attracts more members.

A $10,000 investment in Costco at its 1985 merger with Price Club would be worth approximately $1.5 million today. The stock has compounded at roughly 16% annually for four decades, with remarkable consistency. Costco’s membership renewal rate consistently exceeds 90%, and the company has raised its membership fee only modestly over the years — a testament to the value it provides.

UnitedHealth Group (UNH)

UnitedHealth Group is the quiet giant of compounding. A $10,000 investment in 1990 would be worth approximately $6.5 million today, making it one of the best-performing large-cap stocks of the past 35 years. The company compounded at roughly 21% annually by combining health insurance with Optum, its data analytics and healthcare services division.

UnitedHealth benefits from massive scale, regulatory barriers to entry, and the secular growth of healthcare spending. As the U.S. population ages and healthcare becomes an ever-larger share of GDP, UNH has positioned itself as the indispensable infrastructure layer of the American healthcare system.

Historical Compounders Comparison

Notice something striking in this table. Every single one of these stocks suffered devastating drawdowns at some point. Amazon dropped 94%. Microsoft fell 65%. Berkshire lost half its value. The drawdowns are not bugs in the compounding story — they are features. They are the psychological price you pay for extraordinary long-term returns, and the reason most investors fail to capture them.

The Math of Compounding: Why It Feels Like Magic

Albert Einstein allegedly called compound interest “the eighth wonder of the world.” Whether or not he actually said that, the math backs up the sentiment. Compounding is genuinely counterintuitive — our brains think linearly, but compounding works exponentially, and the difference between the two grows dramatic over time.

The Rule of 72

The Rule of 72 is the simplest tool for understanding compounding. Divide 72 by your annual return rate, and you get the approximate number of years it takes for your money to double.

Look at the difference between 10% and 15% over 30 years. At 10%, your $10,000 becomes about $174,000. At 15%, it becomes $662,000. That extra 5 percentage points of annual return delivers nearly four times as much wealth over three decades. And at 20%, you are looking at $2.4 million. This is why the difference between an average business and a great business matters so enormously to your long-term wealth.

The Hockey Stick Effect

The most psychologically challenging aspect of compounding is that the big money comes at the end. A $10,000 investment growing at 15% annually takes 20 years to reach $163,000. But it takes only 5 more years to reach $328,000, and just 5 more years after that to reach $660,000. The first 20 years generated $153,000 in gains. The last 10 years generated nearly $500,000.

This is why time is the most important variable in compounding. Warren Buffett is worth over $130 billion, but more than 99% of that wealth was accumulated after his 50th birthday. He started investing at age 11 and became a billionaire at 56. But the vast majority of his fortune came in his 60s, 70s, 80s, and 90s.

Charlie Munger put it memorably: “The first rule of compounding: never interrupt it unnecessarily.” Every time you sell a compounder to lock in gains, take a break from the market, or chase a hot new trend, you are resetting the compounding clock — and sacrificing the exponential gains that only come with extended holding periods.

The Tax Advantage of Not Selling

There is another mathematical advantage to holding compounders that many investors overlook: tax deferral. In most jurisdictions, you only owe capital gains tax when you sell. As long as you hold, your unrealized gains continue to compound untaxed. This is what investors call the “tax-free float” — essentially an interest-free loan from the government on your unrealized gains.

Consider two investors who both earn 15% annual returns over 20 years. Investor A holds one stock the entire time and pays taxes only at the end. Investor B trades actively, turning over their portfolio annually and paying 20% capital gains tax each year. After 20 years, Investor A has roughly 30-40% more wealth than Investor B — purely from the tax deferral benefit of holding.

This is one reason why Buffett has famously said his favorite holding period is “forever.” It is not just folksy wisdom — it is mathematically optimal.

Identifying the Next Generation of Compounders

Knowing that Apple and Amazon were compounders in hindsight is easy. The hard part is identifying the next generation of compounders before they deliver their biggest gains. While no one can predict the future with certainty, we can use the framework from the first section to evaluate current candidates that exhibit classic compounder characteristics.

Let us examine several companies that many long-term investors and analysts consider strong compounder candidates as of early 2026. Remember, this is not a recommendation to buy — it is an analytical framework applied to real companies.

NVIDIA (NVDA)

NVIDIA has transformed from a gaming GPU company into the essential infrastructure provider for the AI revolution. The company’s data center revenue has exploded, and its CUDA software ecosystem creates powerful switching costs — developers and enterprises that build on NVIDIA’s platform face significant friction in moving to alternatives.

Compounder case: NVIDIA earns ROIC above 50%, has an enormous and rapidly expanding TAM (data center AI, autonomous vehicles, robotics, edge AI), and dominates its market with roughly 80%+ share in AI training chips. The software moat around CUDA is deep and widening.

Risk factors: Cyclicality in chip demand, increasing competition from AMD and custom silicon (Google TPUs, Amazon Trainium), geopolitical risk around China export restrictions, and extreme valuation premium. NVIDIA would need to grow into a truly massive earnings base to justify current prices as a compounder entry point.

Visa (V) and Mastercard (MA)

Visa and Mastercard are arguably the most textbook compounders in the current market. They operate asset-light payment networks that clip a small percentage of every transaction. They do not take credit risk (that falls on the issuing banks), they require minimal capital investment to grow, and they benefit from the secular shift from cash to digital payments worldwide.

Compounder case: Both companies earn ROIC above 40%, have massive and growing TAM (cash still represents roughly 15-18% of global consumer payments), enjoy network effects that are essentially unassailable, and generate recurring revenue that grows with GDP and inflation. They are the ultimate toll bridges of the global financial system.

Risk factors: Regulatory pressure on interchange fees (particularly in Europe and potentially the U.S.), real-time payment systems like UPI in India or FedNow, and potential disruption from blockchain-based payment networks. However, both companies have shown remarkable ability to adapt and integrate new payment technologies rather than being disrupted by them.

Intuitive Surgical (ISRG)

Intuitive Surgical dominates robotic-assisted surgery with its da Vinci system. The company has an installed base of over 9,000 systems worldwide, and each system generates recurring revenue through instruments and accessories used in each procedure. The razor-and-blade model creates predictable, high-margin revenue streams.

Compounder case: ISRG has a 15+ year head start in robotic surgery, massive switching costs (surgeon training takes years), growing procedures per system, expanding into new surgical categories, and a long runway for global adoption. Only about 3-5% of applicable surgeries are currently performed robotically, suggesting enormous growth potential.

Risk factors: Competition from Medtronic’s Hugo system and Johnson & Johnson’s Ottava platform, regulatory hurdles in new markets, and high system costs that limit adoption in price-sensitive markets. The stock also typically trades at a premium valuation.

S&P Global (SPGI) and Moody’s (MCO)

S&P Global and Moody’s are the Visa and Mastercard of the financial data world. They operate in a regulated duopoly for credit ratings — if you want to issue bonds, you essentially need a rating from at least one of them. This creates pricing power that borders on the absurd.

Compounder case: Both companies earn exceptional ROIC (30%+), have pricing power that rivals any business on the planet, benefit from growing global debt markets, and have expanded into high-growth adjacencies like data analytics and index services. S&P Global’s merger with IHS Markit created a data and analytics powerhouse with significant cross-selling opportunities.

Risk factors: Cyclicality in bond issuance volumes (higher rates reduce issuance), potential regulatory changes to the rating system, and litigation risk. However, these businesses have demonstrated remarkable resilience across market cycles.

Adobe (ADBE)

Adobe’s transition from selling boxed software to a cloud subscription model (Creative Cloud, Document Cloud, Experience Cloud) is one of the most successful business model transformations in software history. The company’s products — Photoshop, Illustrator, Premiere Pro, Acrobat — are the industry standards for creative professionals.

Compounder case: Adobe earns ROIC above 30%, has massive switching costs (creative professionals build their entire workflows around Adobe tools), benefits from the explosion of digital content creation, and is integrating AI (Adobe Firefly) to enhance rather than disrupt its product suite. The subscription model provides predictable, recurring revenue with high retention rates.

Risk factors: Competition from emerging AI-powered design tools like Canva and Figma (whose acquisition by Adobe was blocked by regulators), potential disruption from generative AI that could democratize design, and saturation risk in core creative markets. Adobe needs to successfully integrate AI to maintain its competitive position.

Current Compounder Candidates Comparison

Why Most Investors Can’t Hold Compounders

Here is the paradox of compounding: the strategy is simple, but executing it is brutally difficult. Buy great businesses and hold them for decades. That is it. A child could understand the concept. Yet study after study shows that the vast majority of investors — including professionals — fail to do it.

Dalbar’s annual studies consistently show that the average equity fund investor earns roughly 3-4 percentage points less than the S&P 500 over rolling 20-year periods. Over decades, that gap costs hundreds of thousands or even millions of dollars. The underperformance is not because investors pick bad stocks — it is because they buy and sell at the wrong times, driven by predictable psychological biases.

Loss Aversion and the Pain of Drawdowns

Humans feel the pain of losses roughly twice as intensely as the pleasure of equivalent gains. This is hardwired into our brains from evolutionary survival instincts — losing your food supply was more dangerous than missing an opportunity to gather extra berries.

In investing, loss aversion manifests as panic selling during drawdowns. When Amazon dropped 94% in 2000-2001, every fiber of the average investor’s being screamed “SELL BEFORE IT GOES TO ZERO.” The rational response — recognizing that the business was still growing and the long-term thesis was intact — required fighting against millions of years of evolutionary programming.

Remember: every single compounder on our historical list suffered at least one drawdown of 40% or more. Holding through those drawdowns is the price of admission to life-changing wealth. Most people refuse to pay it.

Anchoring and Regret Aversion

Anchoring bias causes investors to fixate on arbitrary price points. “The stock was $200 last month, now it’s $150 — it’s broken.” Or worse: “The stock is up 300% from my purchase price — I should sell before I give back my gains.” This second form of anchoring is particularly devastating to compounding because it causes investors to sell their biggest winners, cutting off the exponential growth curve precisely when it starts to accelerate.

Peter Lynch called this “pulling the flowers and watering the weeds” — selling your best-performing stocks while holding onto your worst performers, hoping they will recover. This behavior systematically destroys wealth over time because it ensures you never hold a compounder long enough to capture the truly transformative returns.

Boredom and FOMO

Compounding is boring. Holding the same stocks for 10, 20, or 30 years while the financial media breathlessly covers the latest hot trend requires extraordinary discipline. When meme stocks are doubling overnight, when crypto is surging, when the latest AI startup is the talk of every dinner party — sitting on your Visa and Costco shares feels downright painful.

Social media has made this worse. Every day, your feed is filled with screenshots of people making 500% gains in weeks. What the screenshots do not show is the eventual losses that wipe out most of those gains, or the taxes owed on short-term trading profits. Survivorship bias in social media creates a distorted picture that makes patient compounding seem like a fool’s game.

Narrative Changes and Overthinking

Over the life of a compounder, the narrative will change dozens of times. Apple went from “dying company” (1997) to “one-trick pony” (2010, reliant on iPhone) to “growth is over” (2016) to “services will save them” (2020) to “AI play” (2024). At every narrative inflection point, there was a seemingly compelling reason to sell.

The investors who made 280x on Apple from 2003 to 2025 were not smarter than everyone else. They were just less reactive. They focused on the underlying business fundamentals — growing revenue, expanding margins, increasing ecosystem lock-in — rather than the constantly shifting Wall Street narrative.

Practical Solutions for the Behavioral Challenge

Knowing about these biases is not enough — you need systems to counteract them:

• Write an investment thesis before buying. Document why you believe the company is a compounder and what would need to change for you to sell. Review this document during drawdowns instead of checking the stock price.
• Set a review schedule, not a price alert schedule. Review your compounder holdings quarterly or semi-annually based on business fundamentals, not daily based on stock price movements.
• Automate where possible. Set up automatic dividend reinvestment and consider automatic monthly purchases through a recurring investment plan.
• Reduce information intake. Paradoxically, the more financial news you consume, the worse your returns tend to be. Check your portfolio less frequently — monthly or quarterly is enough for a long-term compounder strategy.
• Find an accountability partner. Having someone who can talk you off the ledge during panics — a trusted friend, an advisor, or even a written commitment to yourself — can prevent the impulsive decisions that destroy compounding.

Building a Compounder Portfolio

Understanding individual compounders is valuable, but you also need a framework for assembling them into a portfolio. A compounder portfolio is fundamentally different from a traditional diversified portfolio — it is more concentrated, has lower turnover, and requires a longer time horizon.

Concentration vs. Diversification

Conventional wisdom says to diversify broadly. For a compounder strategy, this needs to be modified. Owning 50 stocks makes it nearly impossible to know each business deeply enough to hold through inevitable drawdowns with conviction. But owning just 3 stocks creates catastrophic risk if one turns out to be wrong.

Most successful compounder investors hold 10 to 20 stocks. This provides enough diversification to survive a company-specific disaster while allowing enough concentration to generate meaningful outperformance. If you have 15 stocks and one turns out to be a 50x winner over 20 years, it will dominate your portfolio returns even if several others are mediocre.

Position Sizing and Adding Over Time

You do not need to build your entire position at once. In fact, there are good reasons not to. Consider starting with a 3-5% allocation to a potential compounder and adding to the position over time as your conviction grows and the business continues to execute.

There is an important nuance here: many investors refuse to add to a position that has already gone up significantly. “I can’t buy it now — it’s 50% higher than when I first bought.” This is anchoring bias in action. If the business is more valuable today than when you first bought — if it has grown earnings, expanded its moat, and increased its addressable market — then paying a higher price for a better business can still be a great investment.

Buffett has consistently added to his Apple position even as the stock rose. He understood that a business that is 50% more valuable is cheap even at a 50% higher stock price.

When to Sell a Compounder

If the default mode is to hold, when should you actually sell? There are only a few legitimate reasons:

1. The competitive moat is permanently impaired. If a technological shift or regulatory change has genuinely destroyed the company’s competitive advantage, it is time to move on. BlackBerry’s smartphone moat was destroyed by the iPhone — that was a genuine sell signal, not a temporary setback.
2. Capital allocation becomes reckless. If management starts making empire-building acquisitions at absurd prices, issuing excessive stock-based compensation, or taking on dangerous levels of debt, the compounding engine may be breaking down.
3. The valuation becomes truly extreme. This is the trickiest sell reason because compounders often look “expensive” on traditional metrics. However, if a stock is trading at 100x earnings with decelerating growth and increasing competition, trimming the position can be prudent. Be honest with yourself — are you selling because the valuation is truly unsustainable, or because you are anchoring to a lower price?
4. You find a dramatically better opportunity. Occasionally, a once-in-a-decade opportunity presents itself, and funding it requires selling an existing holding. This should be rare — if you are frequently finding “better” opportunities, you are probably trading too much.

Sample Portfolio Construction Framework

Here is a framework — not a specific recommendation — for thinking about compounder portfolio construction:

The key principles: let your winners run (do not rebalance by selling compounders just because they have become a large position), add to positions during drawdowns when the thesis is intact, and keep turnover extremely low. The goal is a portfolio where 2-3 stocks become dominant positions over time because they have compounded dramatically — not a perfectly balanced portfolio that is constantly being trimmed and adjusted.

Patience as Your Competitive Edge

In a market obsessed with quarterly earnings beats, algorithmic trading, and instant gratification, patience has become the ultimate contrarian strategy. Most institutional investors are evaluated on quarterly or annual performance. Most retail investors check their portfolios daily. Both groups are structurally incapable of holding stocks for 10 to 20 years.

This creates an enormous opportunity for the minority of investors who can genuinely commit to a multi-decade time horizon. You are competing against hedge funds that face quarterly redemptions, mutual fund managers who get fired for two bad years, and retail traders whose average holding period is measured in days. Your willingness to hold great businesses through the inevitable rough patches is your competitive edge — and it is an edge that will never be arbitraged away because it is rooted in human nature, not information.

As Nick Sleep, one of the most successful long-term investors in history, wrote in his final letter to partners: “The destination is more important than the journey, and almost all of the destination is in the last few years.” He was describing the hockey stick of compounding, and his Nomad Investment Partnership returned over 900% across its 13-year life by holding concentrated positions in Amazon, Costco, and Berkshire Hathaway.

Conclusion

The concept of a compounder is deceptively simple: find businesses with high returns on capital, long reinvestment runways, durable competitive moats, and genuine pricing power — then hold them for as long as those characteristics remain intact. The math is straightforward. The strategy is easy to explain. And yet, compounding remains the most underutilized wealth-building tool available to individual investors.

The historical record is unambiguous. A modest $10,000 investment in businesses like Berkshire Hathaway, Apple, Amazon, Microsoft, Costco, or UnitedHealth Group generated millions of dollars in wealth for investors who had the patience to hold. These were not lucky bets — they were businesses with identifiable compounder characteristics that played out over decades.

Today, companies like Visa, Mastercard, NVIDIA, Intuitive Surgical, S&P Global, Moody’s, and Adobe exhibit many of the same characteristics. Whether they will deliver the same multi-decade compounding returns is uncertain — it always is. But the framework for identifying them is well established, and the odds favor investors who focus on quality businesses at reasonable prices over those who chase momentum, timing, or the next hot trade.

The greatest challenge is not intellectual but emotional. Our brains are wired to react to short-term threats, to feel the pain of losses more acutely than the pleasure of gains, and to seek the dopamine hit of action over the discipline of inaction. The investors who build generational wealth through compounding are not smarter than everyone else — they are simply better at doing nothing.

If you take one thing from this article, let it be this: the next great compounder is almost certainly hiding in plain sight right now. It is a company you have probably heard of, whose products you might use daily, whose competitive advantages are visible to anyone willing to look. The question is not whether you can find it. The question is whether you can hold it.

References

1. Buffett, W. (2024). Berkshire Hathaway Annual Letter to Shareholders. Berkshire Hathaway Inc.
2. Greenwald, B. et al. (2020). Value Investing: From Graham to Buffett and Beyond, 2nd Edition. Wiley.
3. Mauboussin, M. (2023). “Return on Invested Capital: How to Calculate and Interpret ROIC.” Morgan Stanley Investment Management.
4. Dalbar, Inc. (2024). Quantitative Analysis of Investor Behavior (QAIB). Annual Report.
5. Sleep, N. (2014). Final Letter to Partners. Nomad Investment Partnership.
6. Lynch, P. (2000). One Up on Wall Street, Revised Edition. Simon & Schuster.
7. Kahneman, D. (2011). Thinking, Fast and Slow. Farrar, Straus and Giroux.
8. Visa Inc. (2025). Annual Report 2024. SEC Filing.
9. NVIDIA Corporation (2025). Annual Report 2024. SEC Filing.
10. S&P Global Inc. (2025). Investor Presentation Q4 2024.